Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
2003 1
2004 3
2005 2
2006 7
2007 5
2008 2
2009 4
2010 10
2011 14
2012 8
2013 5
2014 6
2015 12
2016 12
2017 7
2018 5
2019 5
2020 6
2021 5
2022 11
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for anastrozole accord
Your search for anastrozol-accord retrieved no results
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had no previous systemic therapy in the advanced setting. ...Both groups also received endocrine the …
We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, H …
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Baselga J, et al. N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7. N Engl J Med. 2012. PMID: 22149876 Free PMC article. Clinical Trial.
The median age was 62 years, 56% had visceral involvement, and 84% had hormone-sensitive disease. Previous therapy included letrozole or anastrozole (100%), tamoxifen (48%), fulvestrant (16%), and chemotherapy (68%). ...Median progression-free survival was 10.6 months and …
The median age was 62 years, 56% had visceral involvement, and 84% had hormone-sensitive disease. Previous therapy included letrozole or …
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Group performance status of 0-2 were recruited and monitored for rising bESR1(mut) during first-line aromatase inhibitor (2.5 mg letrozole, 1 mg …
Women aged at least 18 years with oestrogen receptor-positive, HER2-negative advanced breast cancer and an Eastern Cooperative Oncology Grou …
A Case of Anastrozole-Induced Erythrocytosis.
Kapoor J, Singh N, Agrawal N, Ahmed R, Bhurani D. Kapoor J, et al. Indian J Hematol Blood Transfus. 2019 Jan;35(1):194-195. doi: 10.1007/s12288-018-1022-1. Epub 2018 Oct 1. Indian J Hematol Blood Transfus. 2019. PMID: 30828176 Free PMC article. No abstract available.
The Role of Aromatase Inhibitors in Male Prolactinoma.
Akirov A, Rudman Y. Akirov A, et al. J Clin Med. 2023 Feb 10;12(4):1437. doi: 10.3390/jcm12041437. J Clin Med. 2023. PMID: 36835974 Free PMC article. Review.
OBJECTIVE: this paper systematically reviewed the role of aromatase inhibitors for men with prolactinoma and dopamine-agonist-resistant or persistent hypogonadism following treatment. METHOD: we performed a systematic review of all studies (according to PRISMA guidelines), …
OBJECTIVE: this paper systematically reviewed the role of aromatase inhibitors for men with prolactinoma and dopamine-agonist-resistant or p …
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN. Mehta RS, et al. N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714. N Engl J Med. 2019. PMID: 30917258 Free PMC article. Clinical Trial.
We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. ...The incidence of long-term toxic effects of grade …
We now report final survival outcomes. METHODS: We randomly assigned patients to receive either anastrozole or fulvestrant plus an …
Combination anastrozole and fulvestrant in metastatic breast cancer.
Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Mehta RS, et al. N Engl J Med. 2012 Aug 2;367(5):435-44. doi: 10.1056/NEJMoa1201622. N Engl J Med. 2012. PMID: 22853014 Free PMC article. Clinical Trial.
Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. ...The rates of grade 3 to 5 toxic effects did not differ significantly between the two groups. CONCLUSIONS: The combination of anastrozole and fulvestrant was superior to …
Patients were stratified according to prior or no prior receipt of adjuvant tamoxifen therapy. ...The rates of grade 3 to 5 toxic eff …
Evaluation of Pharmacokinetics and Safety With Bioequivalence of Anastrozole in Healthy Chinese Volunteers: Bioequivalence Study Findings.
Wang Y, Wang T, Fang H, Huang H, Fang L, Zhang X. Wang Y, et al. Clin Pharmacol Drug Dev. 2022 Jun;11(6):687-694. doi: 10.1002/cpdd.1099. Epub 2022 Apr 29. Clin Pharmacol Drug Dev. 2022. PMID: 35485182 Clinical Trial.
Anastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. ...The severity of observed adverse events assessed according to the Common Terminology Criteria for Adverse Events (version CTCAE4.03) was mild, and some of the adv …
Anastrozole is a third-generation aromatase inhibitor that exerts potent anti-breast cancer effects. ...The severity of observed adve …
The effect of anastrozole therapy on final height and sex hormone levels in pubertal boys receiving growth hormone therapy.
Tarçın G, Koç C, Turan H, Ercan O. Tarçın G, et al. Arch Endocrinol Metab. 2023 Nov 17;68:e220524. doi: 10.20945/2359-4292-2022-0524. Arch Endocrinol Metab. 2023. PMID: 37988665 Free PMC article.
The greatest increase for FSH, LH, total and free testosterone and decrease for estradiol levels were observed in the third month after anastrozole was started, albeit remaining within the normal ranges according to the actual pubertal stages. ...These results sugge …
The greatest increase for FSH, LH, total and free testosterone and decrease for estradiol levels were observed in the third month after a …
Major clinical research advances in gynecologic cancer in 2019.
Kim M, Suh DH, Lee KH, Eom KY, Lee JY, Lee YY, Hansen HF, Mirza MR, Kim JW. Kim M, et al. J Gynecol Oncol. 2020 May;31(3):e48. doi: 10.3802/jgo.2020.31.e48. J Gynecol Oncol. 2020. PMID: 32319232 Free PMC article. Review.
Additionally, we conducted a thorough review of emerging data from several clinical trials on PARP inhibitors according to drug, target population, and combined usage. For uterine corpus cancer, we reviewed adjuvant therapy for high-risk disease and chemotherapy in advance …
Additionally, we conducted a thorough review of emerging data from several clinical trials on PARP inhibitors according to drug, targ …
124 results